Vascular Tissue Matrix Market Report 2026

Vascular Tissue Matrix Market Overview

• Vascular Tissue Matrix market size has reached to $1.3 billion in 2025 • Expected to grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Growth Of Vascular Tissue Matrix Market Driven By Rising Adoption Of Minimally Invasive Procedures • Market Trend: Innovative Advances In The Vascular Tissue Matrix Market • North America was the largest region in 2025.

What Is Covered Under Vascular Tissue Matrix Market?

A vascular tissue matrix refers to a biomaterial scaffold designed to support the growth, repair, or regeneration of vascular tissues, which are tissues associated with blood vessels, including arteries, veins, and capillaries. This matrix provides a three-dimensional framework that mimics the extracellular matrix (ECM) of natural vascular tissues, facilitating the attachment, proliferation, and differentiation of cells. The main types of vascular tissue matrix are biologic matrix and synthetic matrix. A biologic matrix is made from natural tissues and cells, typically derived from humans or animals. These matrices are used in medical procedures to replace or repair damaged tissues, promoting natural healing by integrating with the body's own tissues. This matrix is used in various therapeutic areas such as orthopedics, dermatology, cardiology, neurology, oncology, and others and finds application in hospitals, clinics, and others.

What Is The Vascular Tissue Matrix Market Growth Forecast?

The vascular tissue matrix market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising demand for vascular regeneration solutions, increasing investments in tissue engineering, expansion of personalized medicine approaches, growing use of advanced biomaterials, ongoing innovation in scaffold fabrication technologies. Major trends in the forecast period include increasing adoption of biologic vascular scaffolds, rising demand for regenerative cardiovascular therapies, growing use of decellularized tissue matrices, expansion of tissue engineering applications, enhanced focus on biocompatibility and long-term integration.

What Is The Driver Of The Vascular Tissue Matrix Market?

The rising adoption of minimally invasive procedures is expected to propel the growth of the vascular tissue matrix market going forward. Minimally invasive procedures are medical or surgical interventions that require only small incisions or no incisions at all. The demand for minimally invasive procedures is on the rise due to their reduced recovery times, lower risk of complications, and lower postoperative pain compared to traditional surgeries. A vascular tissue matrix is used in minimally invasive procedures to support and regenerate blood vessels without the need for extensive surgery. For instance, in January 2024, Intuitive Surgical Inc., a US-based manufacturer of robotic products, reported that they had placed 415 da Vinci surgical systems (robotic surgical systems that use a minimally invasive surgical approach) in the fourth quarter of 2023, representing a 12% increase compared to 2022. Therefore, the growth of minimally invasive procedures is driving the growth of the vascular tissue matrix industry.

Key Players In The Global Vascular Tissue Matrix Market

Major companies operating in the vascular tissue matrix market are Abbott Laboratories, Medtronic PLC, Baxter International Inc., Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Getinge Group, Integra LifeSciences Corporation, Artivion Inc., CryoLife Inc., LeMaitre Vascular Inc., Cook Medical Inc., Humacyte Inc., BioCardia Inc., Organogenesis Holdings Inc., AxoGen Inc., Collagen Matrix Inc., ACell Inc., Reva Medical Inc.

Global Vascular Tissue Matrix Market Trends and Insights

Major companies operating in the vascular tissue matrix market are increasing their focus on developing innovative products, such as tissue matrix derived from human umbilical cord extracellular matrix (ECM), to gain a competitive edge in the market. A tissue matrix derived from the human umbilical cord extracellular matrix is a scaffold composed of the structural proteins and molecules found in the extracellular matrix of the umbilical cord. For instance, in February 2024, StimLabs LLC, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its novel wound care device, Corplex P. This device, the first graft derived from the human umbilical cord ECM, is designed for treating acute and chronic wounds. It contains connective tissue matrix components, including collagens and glycosaminoglycans like hyaluronic acid, providing a porous scaffold to support cellular infiltration and tissue regeneration. Corplex P is intended to manage various types of wounds, including partial- and full-thickness wounds, pressure ulcers, diabetic ulcers, surgical wounds, and trauma wounds.

What Are Latest Mergers And Acquisitions In The Vascular Tissue Matrix Market?

In April 2023, Aziyo Biologics, a US-based commercially oriented regenerative medicine company, partnered with LeMaitre Vascular Inc. to distribute its cardiovascular product line exclusively in the United States. The collaboration includes products designed from an extracellular matrix derived from porcine small intestine submucosa to enhance healing and reduce inflammation in surgical applications. LeMaitre Vascular Inc. is a US-based medical device company that offers vascular tissue matrix products as part of its cardiovascular portfolio.

What Defines the Vascular Tissue Matrix Market?

The vascular tissue matrix market consists of sales of wound care devices, stent grafts, vascular filters, and synthetic vascular grafts. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vascular Tissue Matrix Market Report 2026?

The vascular tissue matrix market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vascular tissue matrix industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.